Zobrazeno 1 - 10
of 32
pro vyhledávání: '"C Sangrador Pelluz"'
Autor:
M Iglesias Rodrigo, C Sebastián Carrasco, C Sangrador Pelluz, N Meca Casasnovas, F Salazar González, B Tenas Rius, J Nicolás Picó
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8067d0880914d5551923b4e68d3303cf
https://doi.org/10.1136/ejhpharm-2023-eahp.429
https://doi.org/10.1136/ejhpharm-2023-eahp.429
Autor:
C, Ezquer-Garin, R, Ferriols-Lisart, L M, Martinez-López, C, Sangrador-Pelluz, J, Nicolás-Picó, M, Alós-Almiñana
Publikováno v:
Die Pharmazie. 75(5)
This is a report on the chemical stability and physical compatibility of intravenous tedizolid phosphate 0.8 mg/mL-sodium rifampicin 2.4 mg/mL and tedizolid phosphate 0.8 mg/mL-meropenem 4 mg/mL combinations in polypropylene 0.9% sodium chloride infu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0751dffe11d9d1fc772ec031d5d8b4b9
https://pubmed.ncbi.nlm.nih.gov/32393422
https://pubmed.ncbi.nlm.nih.gov/32393422
Autor:
R. Garriga Biosca, J Pardo Pastor, A Manzaneque Gordon, J. Nicolás Picó, C. Sangrador Pelluz, S Gallardo Borge, S. Redondo Capafons, P March López
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Hyperglycaemia is the most frequent complication in patients with parenteral nutrition (PN). Numerous factors may favour its appearance. PURPOSE: Identify the predictive factors of hyperglycaemia in patients with PN in order to guide the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8605f38722c6e9a5db78c5462308e6
https://europepmc.org/articles/PMC7535521/
https://europepmc.org/articles/PMC7535521/
Autor:
S. Redondo Capafons, E Rubio Muñoz, P March, S Gallardo Borge, J Pardo Pastor, R. Tomás Sanz, J. Nicolás Picó, A Mercadal Dalmau, I Santsalvador Font, R. Madridejos Mora, C. Sangrador Pelluz
Publikováno v:
Eur J Hosp Pharm
Background The inappropiate use of antibiotics is leading to the appearance of resistance that, along with the decline in the development of new antibacterials, makes some experts talk about a future post-antibiotic period. Approximately between 80%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d60b359f101f6701b4369b62779b0f33
https://doi.org/10.1136/ejhpharm-2018-eahpconf.146
https://doi.org/10.1136/ejhpharm-2018-eahpconf.146
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 38(1)
To know the possible differences in the toxicity profile of triple therapy with telaprevir between monoinfected and coinfected patients.A retrospective observational study (January 2012- November 2013) of patients with HCV genotype 1, both monoinfect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d6dcc1a0128ce9e6c0ed4029f8429948
https://pubmed.ncbi.nlm.nih.gov/24483856
https://pubmed.ncbi.nlm.nih.gov/24483856
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 37(6)
To study the safety of triple therapy with telaprevir and the time of appearance of the RAM in the treatment of hepatitis C.A retrospective observational study (January 2012- June 2013) of patients with HCV genotype 1 who had completed 12 weeks of tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c68fc19ab3fc002817fc6dc96550f37
https://pubmed.ncbi.nlm.nih.gov/24256011
https://pubmed.ncbi.nlm.nih.gov/24256011
Autor:
C, Sangrador Pelluz, M M, Luis Hidalgo, M, Martínez García, M D, Pérez-Serrano Lainosa, E, Soler Company
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 37(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc8c81511cd565d8ba73b4d99f4021b9
https://pubmed.ncbi.nlm.nih.gov/24128107
https://pubmed.ncbi.nlm.nih.gov/24128107
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 37(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::015cc5de741515634ab8450c60c1d7e3
https://pubmed.ncbi.nlm.nih.gov/23789802
https://pubmed.ncbi.nlm.nih.gov/23789802
Autor:
C Sangrador Pelluz, FJ Maiques Llácer, E Soler Company, P Taberner Bonastre, S García Muñoz, M Monzó Rausell
Publikováno v:
European Journal of Hospital Pharmacy. 21:A106.3-A107
Background Telaprevir is used in the treatment of chronic hepatitis C (HCV). Purpose To find out at what point adverse reactions (ADRs) appear from the start of telaprevir treatment in order to prevent harm and improve management. Materials and metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33ed71d43ecc694d2ac9faf545ac3365
https://doi.org/10.1136/ejhpharm-2013-000436.262
https://doi.org/10.1136/ejhpharm-2013-000436.262
Autor:
C Sangrador Pelluz, FJ Maiques Llácer, E Soler Company, JP Navarro Ferrando, P Taberner Bonastre, L Barrajón Pérez
Publikováno v:
European Journal of Hospital Pharmacy. 21:A107.1-A107
Background Telaprevir is a new drug for the treatment of chronic hepatitis C virus (HCV). Purpose To compare the safety of telaprevir treatment between HCV mono-infected patients and HIV co-infected patients. Materials and methods Retrospective obser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adba090e1b3b964cbcf33429e40435fa
https://doi.org/10.1136/ejhpharm-2013-000436.263
https://doi.org/10.1136/ejhpharm-2013-000436.263